Loading...
Please wait, while we are loading the content...
Similar Documents
Early OCTA Changes of Type 3 Macular Neovascularization Following Brolucizumab Intravitreal Injections
| Content Provider | MDPI |
|---|---|
| Author | Maria, Vadalà Gigon, Anthony Bonfiglio, Vincenza M. E. Reibaldi, Michele Eandi, Chiara M. |
| Copyright Year | 2022 |
| Description | Background and Objectives: Brolucizumab is a novel anti-vascular endothelial growth factor (VEGF), whose efficacy has been shown in the Hawk and Harrier phase 3 clinical studies. The goal of the present case series is to report initial results of brolucizumab intravitreal injections (IVI) on type 3 neovascularization in neovascular age-related macular degeneration (nAMD), evaluated by optical coherence tomography angiography (OCTA). Materials and Methods: This is a bicentric retrospective case series. Patients with newly diagnosed type 3 MNV treated with brolucizumab IVI and at least 6 months follow-up were enrolled. OCTA en face images and B-scans were analyzed for lesions at baseline, 1 month, 3 months, and 6 months. Whenever detectable, lesion area on outer retina and choriocapillaris layers was measured. Results: Twelve eyes of 12 patients were included into the study. The most consistent OCTA sign at baseline was the presence of a vascular tuft in the outer retina (100%). The highest response was achieved at 3 months, with statistically significant decrease in lesion detection in the outer retina, in the choriocapillaris, and outer retinal lesion size. At 6 months, 58% of outer retinal lesions had disappeared. Conclusions: Brolucizumab IVI shows a good short-term efficacy for the treatment of type 3 neovascularizations. Further studies with greater number of patients and longer follow-up are warranted to confirm these findings. |
| Starting Page | 1180 |
| e-ISSN | 16489144 |
| DOI | 10.3390/medicina58091180 |
| Journal | Medicina |
| Issue Number | 9 |
| Volume Number | 58 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2022-08-30 |
| Access Restriction | Open |
| Subject Keyword | Medicina Ophthalmology Neovascular Age-related Macular Degeneration Type 3 Neovascularization Retinal Angiomatous Proliferation Brolucizumab Optical Coherence Tomography Angiography Intravitreal Injection |
| Content Type | Text |
| Resource Type | Article |
